LL-37 (cathelicidin) is the only human cathelicidin peptide. It is studied for direct antimicrobial activity, wound healing, and modulation of innate immunity in preclinical research.

Is LL-37 FDA-approved?

No. LL-37 is not approved by the FDA or any major regulator for clinical use. Research-peptide vendors sell it for laboratory research only.

What is the half-life of LL-37?

Pepticker does not publish a quantitative plasma half-life for LL-37 — values reported in the published literature vary by route and model, and circulating pharmacokinetics in humans are not as well characterized as for prescription peptides.

What dose of LL-37 is used in research?

Doses reported in published preclinical studies vary by species, route, and antimicrobial or immune endpoint. Pepticker does not publish a dosing protocol — refer to the original literature for the model you are reproducing.

What is LL-37 commonly stacked with?

Researchers most commonly pair LL-37 with KPV for mucosal-immunity work and with Thymosin Alpha-1 in immune-modulation protocols, based on published preclinical research.

LL-37 is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

healing

LL-37

Antimicrobial cathelicidin

0 vendors tracked0 live pricesLast crawl: warming up

About

The only human cathelicidin, studied for antimicrobial activity, wound healing, and modulation of innate immunity.

Also known as: Cathelicidin, Human cationic antimicrobial peptide

Reconstitution calculator

For research purposes only. Not for human consumption. Always verify calculations independently.

VialPeptide mass in vial (mg)mgBacteriostatic water added (mL)mL

DoseDesired dose

Syringe

How reconstitution works · Understanding syringe units

Cost-per-dose recalculates as you adjust the calculator above.

§ Frequently asked

Common questions about LL-37

What is LL-37?: LL-37 (cathelicidin) is the only human cathelicidin peptide. It is studied for direct antimicrobial activity, wound healing, and modulation of innate immunity in preclinical research.
Is LL-37 FDA-approved?: No. LL-37 is not approved by the FDA or any major regulator for clinical use. Research-peptide vendors sell it for laboratory research only.
What is the half-life of LL-37?: Pepticker does not publish a quantitative plasma half-life for LL-37 — values reported in the published literature vary by route and model, and circulating pharmacokinetics in humans are not as well characterized as for prescription peptides.
What dose of LL-37 is used in research?: Doses reported in published preclinical studies vary by species, route, and antimicrobial or immune endpoint. Pepticker does not publish a dosing protocol — refer to the original literature for the model you are reproducing.
What is LL-37 commonly stacked with?: Researchers most commonly pair LL-37 with KPV for mucosal-immunity work and with Thymosin Alpha-1 in immune-modulation protocols, based on published preclinical research.
Is LL-37 legal?: LL-37 is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.

Research use only. The compounds listed on this page are not approved for human use through research-chemical channels. Nothing on this page is medical advice. Consult a qualified clinician before considering any peptide protocol. See affiliate disclosure and our scoring methodology.

Keep exploring

Common questions about LL-37

More on LL-37 & related research